Journal
MEDICINE
Volume 99, Issue 16, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MD.0000000000019739
Keywords
B cell lymphoma; B cell maturation antigen; chimeric antigen receptor T; CD19; multiple myeloma
Categories
Funding
- National Science Foundation of China [81670150, 81800160]
Ask authors/readers for more resources
Rationale: B cell lymphoma can co-occur with multiple myeloma (MM), and the prognosis in this case is usually poor. We propose the combination of CD19-chimeric antigen receptor (CAR) T cells and BCMA-CAR T cells for the treatment of such patients to obtain a superior prognosis. Patient concerns: We present a 50-year-old patient with previous B cell lymphoma and subsequent multiple myeloma (MM). Diagnosis: A diagnosis of B cell lymphoma and MM was made. Interventions: The patient was treated with a combination of haploidentical CD19-chimeric antigen receptor (CAR) T cells and BCMA-CAR T cells. Outcomes: After CAR T cell therapy, the monoclonal plasma cells in the bone marrow and M protein disappeared. Lessons: The combination therapy of CD19- and BCMA-CAR T cells is an effective measure to treat patients with concomitant or borderline cases of B cell lymphoma and MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available